Search research articles
Contact Us
Filters
Showing results (11-20 of 93) with videos related to
Page
of 10
Sort By:
JAMA
|
May 8, 2019
Racial Disparities in Low-Risk Prostate Cancer
Behfar Ehdaie, Sigrid Carlsson, Andrew Vickers
Evidence-Based Medicine
|
January 14, 2011
Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions
Monique J Roobol, Sigrid Carlsson, Jonas Hugosson
Nature Reviews. Urology
|
March 14, 2012
Prostate cancer: modeling the outcomes of prostate cancer screening
Stacy Loeb, Sigrid Carlsson, R Scott Braithwaite
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2007
Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study
Sigrid Carlsson, Gunnar Aus, Catrin Wessman, et al.
Annals of Internal Medicine
|
April 5, 2012
Screening for prostate cancer
Sigrid Carlsson, Andrew Vickers, Hans Lilja, et al.
European Urology
|
January 14, 2014
It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening
Andrew Vickers, Sigrid Carlsson, Vincent Laudone, et al.
Lakartidningen
|
November 4, 2010
[Comments on the editorial on compulsory scrutiny of internship: regular quality assurance more important than centralized local]
Sigrid Carlsson, Paulin Andréll, Ulla Strandman, et al.
BJU International
|
May 1, 2012
The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial
Maria Frånlund, Sigrid Carlsson, Johan Stranne, et al.
Deutsches Arzteblatt International
|
April 9, 2026
The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks
Peter Albers, Sigrid Carlsson, Agne Krilaviciute, et al.
European Urology Oncology
|
March 18, 2026
Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway
Anwar R Padhani, Sigrid Carlsson, Ola Bratt, et al.
Page
of 10
Search research articles
Search
Showing results (11-20 of 93) with videos related to
Sort By:
Page
of 10
JAMA
|
May 8, 2019
Racial Disparities in Low-Risk Prostate Cancer
Behfar Ehdaie, Sigrid Carlsson, Andrew Vickers
Evidence-Based Medicine
|
January 14, 2011
Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions
Monique J Roobol, Sigrid Carlsson, Jonas Hugosson
Nature Reviews. Urology
|
March 14, 2012
Prostate cancer: modeling the outcomes of prostate cancer screening
Stacy Loeb, Sigrid Carlsson, R Scott Braithwaite
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2007
Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study
Sigrid Carlsson, Gunnar Aus, Catrin Wessman, et al.
Annals of Internal Medicine
|
April 5, 2012
Screening for prostate cancer
Sigrid Carlsson, Andrew Vickers, Hans Lilja, et al.
European Urology
|
January 14, 2014
It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening
Andrew Vickers, Sigrid Carlsson, Vincent Laudone, et al.
Lakartidningen
|
November 4, 2010
[Comments on the editorial on compulsory scrutiny of internship: regular quality assurance more important than centralized local]
Sigrid Carlsson, Paulin Andréll, Ulla Strandman, et al.
BJU International
|
May 1, 2012
The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial
Maria Frånlund, Sigrid Carlsson, Johan Stranne, et al.
Deutsches Arzteblatt International
|
April 9, 2026
The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks
Peter Albers, Sigrid Carlsson, Agne Krilaviciute, et al.
European Urology Oncology
|
March 18, 2026
Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway
Anwar R Padhani, Sigrid Carlsson, Ola Bratt, et al.
Page
of 10